Edwards Lifesciences (NYSE: EW) reported Q3 EPS of $0.51, $0.07 better than the analyst estimate of $0.44. Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $1.08 billion.

"I am very proud of the way our passionate team is serving patients during this difficult period. Our supply chain has delivered and our field team has continued to support the dedicated clinicians that count on Edwards," said Michael A. Mussallem, chairman and CEO. "We are pleased to report better-than-expected third quarter results despite the challenges of the ongoing COVID pandemic."

GUIDANCE:

Edwards Lifesciences sees FY2020 EPS of $1.85-$1.95, versus prior of $1.75-$1.95 and the consensus of $1.84.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.